» Articles » PMID: 32303598

Repurposing Molecular Imaging and Sensing for Cancer Image-Guided Surgery

Overview
Journal J Nucl Med
Specialty Nuclear Medicine
Date 2020 Apr 19
PMID 32303598
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

Gone are the days when medical imaging was used primarily to visualize anatomic structures. The emergence of molecular imaging (MI), championed by radiolabeled F-FDG PET, has expanded the information content derived from imaging to include pathophysiologic and molecular processes. Cancer imaging, in particular, has leveraged advances in MI agents and technology to improve the accuracy of tumor detection, interrogate tumor heterogeneity, monitor treatment response, focus surgical resection, and enable image-guided biopsy. Surgeons are actively latching on to the incredible opportunities provided by medical imaging for preoperative planning, intraoperative guidance, and postoperative monitoring. From label-free techniques to enabling cancer-selective imaging agents, image-guided surgery provides surgical oncologists and interventional radiologists both macroscopic and microscopic views of cancer in the operating room. This review highlights the current state of MI and sensing approaches available for surgical guidance. Salient features of nuclear, optical, and multimodal approaches will be discussed, including their strengths, limitations, and clinical applications. To address the increasing complexity and diversity of methods available today, this review provides a framework to identify a contrast mechanism, suitable modality, and device. Emerging low-cost, portable, and user-friendly imaging systems make the case for adopting some of these technologies as the global standard of care in surgical practice.

Citing Articles

Optical molecular imaging technology and its application in precise surgical navigation of liver cancer.

He P, Tang H, Zheng Y, Xu X, Peng X, Jiang T Theranostics. 2025; 15(3):1017-1034.

PMID: 39776802 PMC: 11700863. DOI: 10.7150/thno.102671.


Biological Activity of Natural and Synthetic Peptides as Anticancer Agents.

Bauso L, La Fauci V, Munao S, Bonfiglio D, Armeli A, Maimone N Int J Mol Sci. 2024; 25(13).

PMID: 39000371 PMC: 11242495. DOI: 10.3390/ijms25137264.


Multi-wavelength interference phase imaging for automatic breast cancer detection and delineation using diffuse reflection imaging.

Mahmoud A, El-Sharkawy Y Sci Rep. 2024; 14(1):415.

PMID: 38172105 PMC: 10764793. DOI: 10.1038/s41598-023-50475-9.


Peptide-Based Agents for Cancer Treatment: Current Applications and Future Directions.

Nhan N, Yamada T, Yamada K Int J Mol Sci. 2023; 24(16).

PMID: 37629112 PMC: 10454368. DOI: 10.3390/ijms241612931.


Pre- and Intraoperative Visualization of GRPR-Expressing Solid Tumors: Preclinical Profiling of Novel Dual-Modality Probes for Nuclear and Fluorescence Imaging.

Verhoeven M, Handula M, van den Brink L, de Ridder C, Stuurman D, Seimbille Y Cancers (Basel). 2023; 15(7).

PMID: 37046825 PMC: 10093582. DOI: 10.3390/cancers15072161.


References
1.
Stoffels I, Morscher S, Helfrich I, Hillen U, Leyh J, Lehy J . Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging. Sci Transl Med. 2015; 7(317):317ra199. DOI: 10.1126/scitranslmed.aad1278. View

2.
Barroso E, Smits R, van Lanschot C, Caspers P, Ten Hove I, Mast H . Water Concentration Analysis by Raman Spectroscopy to Determine the Location of the Tumor Border in Oral Cancer Surgery. Cancer Res. 2016; 76(20):5945-5953. DOI: 10.1158/0008-5472.CAN-16-1227. View

3.
Mondal S, Gao S, Zhu N, Habimana-Griffin L, Akers W, Liang R . Optical See-Through Cancer Vision Goggles Enable Direct Patient Visualization and Real-Time Fluorescence-Guided Oncologic Surgery. Ann Surg Oncol. 2017; 24(7):1897-1903. PMC: 5503161. DOI: 10.1245/s10434-017-5804-8. View

4.
Stammes M, Bugby S, Porta T, Pierzchalski K, Devling T, Otto C . Modalities for image- and molecular-guided cancer surgery. Br J Surg. 2018; 105(2):e69-e83. DOI: 10.1002/bjs.10789. View

5.
Sondak V, King D, Zager J, Schneebaum S, Kim J, Leong S . Combined analysis of phase III trials evaluating [⁹⁹mTc]tilmanocept and vital blue dye for identification of sentinel lymph nodes in clinically node-negative cutaneous melanoma. Ann Surg Oncol. 2012; 20(2):680-8. PMC: 3560941. DOI: 10.1245/s10434-012-2612-z. View